ストックスクリーナーアプリを入手
5.60
1.23%
-0.07
プレマーケット:
5.60
Mannkind Corp (MNKD) 最新ニュース
MannKind Corp Is Suddenly Everywhere – Is MNKD the Next Sleeper Stock You’ll Regret Ignoring? - AD HOC NEWS
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
MannKind (MNKD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MNKD (MannKind) ROCE % : 17.64% (As of Sep. 2025) - GuruFocus
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years - Yahoo Finance
How Pediatric FUROSCIX Expansion And New Patents At MannKind (MNKD) Has Changed Its Investment Story - simplywall.st
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? - Stocktwits
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - Yahoo Finance
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - The Motley Fool
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
FDA approves FUROSCIX for pediatric patients weighing 43kg or more By Investing.com - Investing.com South Africa
FDA approves FUROSCIX for pediatric patients weighing 43kg or more - Investing.com
MannKind Corporation Announces FDA Approval of FUROSCIX® for Pediatric Use and Patent Issuance for FUROSCIX ReadyFlow™ Autoinjector - Quiver Quantitative
Shot for fluid buildup could help kids and work at home in 10 seconds - Stock Titan
Can MannKind Corporation stock hit record highs again2025 Valuation Update & Consistent Growth Stock Picks - ulpravda.ru
Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Insider Sell: Michael Castagna Sells 65,804 Shares of MannKind C - GuruFocus
Is MannKind Corporation stock affected by interest rate hikesMarket Movement Recap & Reliable Intraday Trade Alerts - DonanımHaber
How MannKind Corporation stock performs in weak economyMarket Growth Report & Weekly Top Gainers Alerts - Улправда
Insider Sell: Michael Castagna Sells 42,116 Shares of MannKind C - GuruFocus
MannKind Corporation (NASDAQ:MNKD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MannKind (NASDAQ:MNKD) CEO Michael Castagna Sells 21,310 Shares - MarketBeat
MannKind (NASDAQ: MNKD) adds audited and pro forma scPharma results to merger filing - Stock Titan
MannKind (MNKD): Evaluating Valuation After FDA Acceptance of the FUROSCIX ReadyFlow Autoinjector sNDA - simplywall.st
Short Squeeze: Will SHPH stock gain from lower inflation2025 Market WrapUp & Free Weekly Watchlist of Top Performers - moha.gov.vn
The Bull Case For MannKind (MNKD) Could Change Following FDA Review Of FUROSCIX ReadyFlow Autoinjector - simplywall.st
MannKind stock price target raised to $9 by Leerink on Tyvaso DPI royalties - Investing.com
MannKind (NASDAQ:MNKD) CEO Michael Castagna Sells 107,920 Shares of Stock - MarketBeat
MannKind (MNKD) Valuation Check After FDA Filing Progress for FUROSCIX ReadyFlow Autoinjector - simplywall.st
Mannkind EVP Thomson sells $823k in shares By Investing.com - Investing.com South Africa
Insider Selling: Michael Castagna Sells Shares of MannKind Corp (MNKD) - GuruFocus
MNKD FinancialsIncome Statement - Quiver Quantitative
Mannkind EVP Thomson sells $823k in shares - Investing.com
Mannkind CEO Castagna sells $601k in shares By Investing.com - Investing.com UK
Mannkind CEO Castagna sells $601k in shares - Investing.com
MannKind Corp Executives Sell Shares - TradingView — Track All Markets
VP Thomson Sells 147,780 ($823.1K) Of MannKind Corp [MNKD] - TradingView
Is MannKind Corporation (NNFN) stock undervalued after correctionWeekly Investment Report & Growth Focused Stock Reports - Newser
How MannKind Corporation (NNFN) stock moves in volatile trading sessionsJuly 2025 EndofMonth & Weekly Momentum Stock Picks - Newser
MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients (NASDAQ:MNKD) - Seeking Alpha
Is There Now an Opportunity in MannKind After This Year’s Share Price Pullback? - Yahoo Finance
MAI Capital Management Reduces Stock Holdings in MannKind Corporation $MNKD - MarketBeat
Can MannKind Corporation (NNFN) stock attract analyst upgradesQuarterly Profit Report & AI Based Buy and Sell Signals - Newser
Can MannKind Corporation (NNFN) stock sustain double digit ROEMarket Movement Recap & Long Hold Capital Preservation Plans - Newser
FDA Reviewing 10-Second Treatment for Edema in Heart Failure - Diagnostic and Interventional Cardiology
MannKind (MNKD) Awaits FDA Decision on Furoscix Autoinjector - GuruFocus
FDA accepts MannKind’s sNDA for ReadyFlow Autoinjector - Investing.com
MannKind (MNKD) Awaits FDA Decision on FUROSCIX ReadyFlow Autoin - GuruFocus
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease - The Manila Times
MannKind Corporation Announces FDA Acceptance of sNDA for FUROSCIX ReadyFlow™ Autoinjector, Targeting Improved Management of Chronic Heart Failure and Kidney Disease - Quiver Quantitative
MannKind (Nasdaq: MNKD) lands FDA sNDA review, PDUFA July 26, 2026 for ReadyFlow - Stock Titan
Geode Capital Management LLC Grows Position in MannKind Corporation $MNKD - MarketBeat
0.57%
大文字化:
|
ボリューム (24 時間):